Compare TSI & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSI | BNR |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.7M | 252.7M |
| IPO Year | 1995 | 2019 |
| Metric | TSI | BNR |
|---|---|---|
| Price | $4.60 | $16.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 251.1K | 15.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $136.32 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.57 | $2.18 |
| 52 Week High | $5.06 | $41.72 |
| Indicator | TSI | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 36.37 | 32.83 |
| Support Level | $4.58 | $15.64 |
| Resistance Level | $4.96 | $24.23 |
| Average True Range (ATR) | 0.04 | 2.01 |
| MACD | 0.01 | -0.74 |
| Stochastic Oscillator | 23.68 | 18.33 |
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.